The efficacy and safety of datopotamab deruxtecan (Dato-DXd) in advanced solid tumors: a systematic review and meta-analysis.

Eur J Med Res · 2025 · PMC12751586 · PMID 41462360

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The two included RCTs provided robust evidence: Aditya Bardia 2025 demonstrated that Dato-DXd significantly improved PFS and showed a trend toward improved OS compared to single-agent chemotherapy.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.